【高血压英文课件】Hypertension-in-CKD整理_第1页
【高血压英文课件】Hypertension-in-CKD整理_第2页
【高血压英文课件】Hypertension-in-CKD整理_第3页
【高血压英文课件】Hypertension-in-CKD整理_第4页
【高血压英文课件】Hypertension-in-CKD整理_第5页
已阅读5页,还剩50页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

HypertensioninCKDMichaelJCasey,MDWakeNephrologyAssociatesHypertensionStatsHTNaffectsapproximately1billionworldwide$500billionindirectcostsContinuous,consistentandindependentrelationshipbetweenBPandCadsForthoseage40-70,eachincreasedincrementof20/10mmHginBPdoublestheriskofCVDacrosstheentireBPrangeof115/75to185/115.Only35%ofhypertensivepatientsontreatmentareundercontrol.HypertensionasDefinedbyJNCVII120/80-normal;“optimal”121-139/80-89-“pre-hypertension”ControversialMoreahealthpolicystatement140-160/90-100-Stage1Hypertension>160/100-Stage2HypertensionMeasurementofBloodPressureSeatedpositionwitharmsupportedidealAllowpatienttosettleforseveralminutesPropersizedcuffBladdertoencircle80–100%armBladderwidth40-50%ofarmConfirm2readings5minutesapartinbotharmsforinitialdiagnosisIftakeninwristorlegs,thecuffmustbeattheleveloftheheartBPMeasurementHomeBPMonitoringSelfreadingsorcontinuousambulatorymonitoringHelpfuladjuncttoofficereadingsMorereadingsinpatientsusualenvironmentBettercorrelatedwithcardiovascularoutcomesImprovespatientcomplianceHelpsclarifysymptomsDefinesmaskedandwhitecoathypertensionHomeBPMonitoringPatientsneedtobetaughtpropermethodsNowristcuffsSemi-automatedelectroniccuffsCuffneedstobecheckedagainstofficereadingsFrequencyofmonitoringcanvaryAllcurrentoutcomedata/guidelines/trailsarefromofficereadingsAmbulatoryBPMonitoringAmbulatoryBPMonitoringAmbulatoryBPMonitoringMorereproduciblethanofficemeasurementsHelpfulinearlydiagnosisUnexplainedmicroalbuminuriaorLVHWhiteCoatHypertensionResistantHypertensionNolongtermstudiesyetPrevalenceofHTNinCKDHypertensioninCKD80%ofpatientswithCKDhaveHBPMoststartwithessentialhypertensionAsGFRdecreasesitismoredependentonsalt/waterretentionfromdecreasedGFRCKDpatientsalsohavederangementsintheRenin/Angiotensin/AldosteronesystemTreatmentofHypertensionGoaldependsondiseasestate<130/80ifDM,CKD,CVDz<125/75ifCKDwithproteinuriaSBPistheissueintheoldDiastolicHBPisaproblemoftheyoungReachingthetargetismoreimportantthanhowyougetthereMultipleinterventionsarenecessaryinmostHypertensiveEmergenciesHypertensionisachronicoutpatientdiseasewithrareacutesideeffectsHeadache,MSchanges,ICH,Papilledema,CHF,Angina,Renalfailurewithhematuria,HemorrhageareemergenciesrequirehospitalizationOtherwisetreatasymptomaticsevereHBPoverdays/weeksClonidineeffectiveforoutpatientacuteBPloweringHoldESAProgressionofCKDandBPBP=COXSVRBP=HRXStrokeVolumeXSVRCO=cardiacoutputSVR=systemicvascularresistanceBPFormulaLifestyleModificationFirst(Always)LowSalt(3gm/day)DASHdietExerciseTobaccoAlcoholSleepApneaNSAIDSDecongestantsDietPillsRenininhibitorsRAASAgentsACEInhibitorscaptopril,enalapril,lisinopril,ramipril…AngiotensinReceptorBlockerslosartan,irbesartan,valsartan,telmisartan…DirectReninInhibitors-aliskirenAldosteroneReceptorBlockersspironolactone,eplerenoneDrugsofChoiceinCKDNotinpregnancyACEI/ARBinCKDTrialPOPULATIONDRUGViberti;JAMA94Type1DMCaptoprilREIN,KI98NephroticRamiprilAASK;JAMA02AAptswCKDRamiprilIRMA2;NEJM01Type2DMValsartanIDNT;NEJM01Type2DMIrbesartanRENAAL;NEJM01Type2DMLosartanMicro-HopeHighriskCVDzRamiprilGlomerularPerfusionACEInhibitorsFirstclassdrugforallCKDpatientsShouldbeconsideredinallstagesIftoleratedthenreduceddevelopmentofESRD,CKDprogressionBestoutcomedatainproteinuricCKDAngioedemaandcoughHyperkalemiaandworseningrenalfunctionAngiotensinReceptorBlockersNextchoiceafterACEIbecauseofcostEqualoutcomedataatthispointNoCoughSameissueswithhyperkalemiaandARFCombowithACEIcomingunderfireDirectReninInhibitorsAliskiren(Tekturna)isonlydrugFirstnewantihypertensiveclassin15yearsPromisingrenal/CHFdatabutnohardoutcomesMaybeusefulforproteinuriareductionincombowithARBGIupsetSameissueofhyperkalemiaandARFaswithallRAASagentsAldosteroneBlockersPotassiumsparingdiureticsCanboostefficacyofloopdiureticsImprovessurvivalinCHFpatientsReductioninproteinuria+/-otherRAASagentsGynecomastiawithspironolactoneSameissueofhyperkalemiaandARFDiureticsKeytoHBPmanagementinnon-ESRDCKDRAASagentsynergyThiazides:hydrochlorothiazide;chlorthalidone,metolazoneK-Sparing:amiloride,triamterene,spironolactone,eplerenoneLoops:furosemide,bumetanide,torsemideThiazideDiureticsJNCfirstchoiceBPmedVeryeffectiveinmultipletrialsOftenavailableincombowithRAASagentLowK,increaseBG,lipidsatdose>25mgIneffectiveatGFR<50CanboostefficacyofloopdiureticsLoopDiureticsNecessarytomaintainvolumestatusinGFR<50FurosemideisclassicbutshorthalflifesopoorforHBPBumetanideissamebutbetterabsorbedTorsemidehasmuchlongerhalf-lifeandismychoicenowthatitisgenericTitratetoincreaseUOPthenincreasefrequencyLowpotassiumismainissue,especiallywiththiazides(metolazone)BetaBlockersSelectiveBetaBlockersAtenolol,metoprolol,bisoprolol,nebivololNon–selectiveBetaBlockersPropranololAlpha–BetaBlockersLabetolol,carvedololBetaBlockersNextclassinCKDpatientsReducesHR,SVandalsoreninReducesincidenceofsuddencardiacdeathandarrhythmiasReducesCVeventsinCHF,post-MICounter-actsreflexincreaseinHR/COinducedbyvasodilatorsanddiureticsBetaBlockersCarvedolol,labetololarebetterforHBPAtenolol,metoprololbetterforCHF,HRreductionandarrhythmiaPropranololforascites/cirrhosis,anxietyBradycardiaandfatiguearemainsideeffectsCentralAdrenergicAgentsClonidineispredominantdrugProbablysamebenefitsasbblockersNostudiesandneverwillbeSynergywithbblockersdebatableDrymouth,fatigue,t.i.d.,bradycardiaGoodforacuteHBP/prnusePatchavailableMethyldopaforHBPinpregnancyDihydropyridineCalciumChannelBlockersNifedipine,amlodipine,felodipineDirectvasodilatorsVeryeffective–prob4thdrugofchoiceCancauseperipheraledemaespeciallyinfemalesNoeffectonHR,CHFIncreaseGFR,proteinuriaGlomerularPerfusionNon-DihydropyridineCCB’sDiltiazemandVerapamilReduceHRandLowerBPArrhythmiacontrolReductioninproteinuriabutnorenaloutcomesEdema,bradycardia,gingivalhyperplasia,CyP450interactionsOtherVasodilatorsAlphablockers–doxazosin,terazosin,prazosinHelpwithBHPOncedailyOrthostatichypertension,tachycardia,CHFHydralazineImprovedoutcomesinAAwithCHFBIDorTIDLupussyndromeModeratelyeffectiveMinoxidilMostpotentantihypertensiveagentSeverereboundtachycardiaandedemaNeedbetablockerandloopdiureticHairgrowthPericarditisInexpensiveHypertensioninESRDGreatareaofdebateRAASAgentsandBetablockersmayimproveoutcomesinnon-RCTsWhatiscorrectmeasurement?Pre-HDBPPost-HDBPHomeBPWhentotake/holdBPMedsHypertensioninESRDHypertensioninESRDHypertensioninESRDHypertensioninESRDJ-shapedcurveofsurvivalvsBPinESRDBettersurvivalwithmoderateHBPOnlycomparedtootherESRD?Skewedbyyoungpatients?SkewedbycardiomyopathyMostHBPisduetoinadequatevolumecontrolDecreaseinterdialyticweightgainChallengeweightLongerHDtimes(daily,nocturnal,PD)TreatmentofHBPinESRDGraduallychallengeweighteachHDNoedemaCrampingLowBPManagementofintradialyticHBPUFprofilingNa+modelingLowerdialysatetemperatureCarnitenelevelsTreatmentofHBPinESRDDonotholdBetablockers/Clo

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论